{"id":2260,"date":"2026-02-25T12:00:28","date_gmt":"2026-02-25T11:00:28","guid":{"rendered":"https:\/\/dextechmedical.com\/?p=2260"},"modified":"2026-02-25T11:22:29","modified_gmt":"2026-02-25T10:22:29","slug":"half-year-report-july-1-december-31-2025","status":"publish","type":"post","link":"https:\/\/dextechmedical.com\/en\/half-year-report-july-1-december-31-2025\/","title":{"rendered":"Half-year report July 1 &#8211; December 31, 2025"},"content":{"rendered":"<p>Summary of the second quarter (2025-10-01 \u2013 2025-12-31)<\/p>\n<ul>\n<li>Net sales amounted to MSEK 0 (0.0)<\/li>\n<li>Operating profit\/loss amounted to MSEK -1.7 (-1.1)<\/li>\n<li>Earnings per share* SEK -0.09 (-0.05)<\/li>\n<li>More than 80 per cent of patients transitioned from progressive to stable disease following completion of treatment.<\/li>\n<li>The study demonstrates a favorable safety profile, with no serious OsteoDex-related adverse events reported.<\/li>\n<\/ul>\n<p>&nbsp;<\/p>\n<p>Summary of the first half-year (2025-07-01 \u2013 2025-12-31)<\/p>\n<ul>\n<li>Net sales amounted to MSEK 0 (0.0)<\/li>\n<li>Operating profit\/loss amounted to MSEK -3.0(-2.4)<\/li>\n<li>Earnings per share* SEK -0.16 (-0.11)<\/li>\n<li>Cash and cash equivalents at the end of the period amounted to MSEK 2 (14.7)<\/li>\n<\/ul>\n<p>&nbsp;<\/p>\n<p><em>Earnings per share are calculated on the average number of shares outstanding during the period. <\/em><\/p>\n<p><em>Amounts in brackets refer to the corresponding period of the previous year, except for cash and cash equivalents which relate to amounts at the end of the previous financial year.<\/em><\/p>\n<p>&nbsp;<\/p>\n<p>Comments from the CEO<\/p>\n<p>The Company\u2019s Phase I\/IIa study of OsteoDex (ODX) for the treatment of patients with relapsed\/refractory multiple myeloma, conducted at Uddevalla Hospital and Karolinska University Hospital, is approaching completion and all patients are expected to have completed treatment by the end of February 2026.<\/p>\n<p>The results demonstrate a favourable safety profile, with no serious ODX-related adverse events reported, and a majority of patients achieving stable disease following completion of treatment. Follow-up data further indicate that, in certain cases, the treatment effect persists for several months after completion of therapy without the need for additional anti-cancer treatment.<\/p>\n<p>The results to date are encouraging and will now be supplemented with additional analyses. The Clinical Study Report (CSR) is expected to be finalised during the second quarter of 2026.<\/p>\n<p>The Company has previously communicated that existing funding would secure operations until the end of 2026. Following updated cost forecasts and based on current liquidity, the Board of Directors now assesses that working capital is sufficient to finance current operations at least until the end of 2028.<\/p>\n<p><em>Anders R Holmberg<\/em><\/p>\n<p><a href=\"https:\/\/dextechmedical.com\/wp-content\/uploads\/DexTech-Half-year-report-July-December-2025.pdf\">DexTech &#8211; Half-year report July &#8211; December 2025<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Summary of the second quarter (2025-10-01 \u2013 2025-12-31) Net sales amounted to MSEK 0 (0.0) Operating profit\/loss amounted to MSEK -1.7 (-1.1) Earnings per share* SEK -0.09 (-0.05) More than [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[3],"tags":[],"class_list":["post-2260","post","type-post","status-publish","format-standard","hentry","category-okategoriserade-en"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.5 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Half-year report July 1 - December 31, 2025 | DexTech<\/title>\n<meta name=\"description\" content=\"Summary of the second quarter (2025-10-01 \u2013 2025-12-31) Net sales amounted to MSEK 0 (0.0) Operating profit\/loss amounted to MSEK -1.7 (-1.1) Earnings per\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/dextechmedical.com\/?p=2256\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Half-year report July 1 - December 31, 2025 | DexTech\" \/>\n<meta property=\"og:description\" content=\"Summary of the second quarter (2025-10-01 \u2013 2025-12-31) Net sales amounted to MSEK 0 (0.0) Operating profit\/loss amounted to MSEK -1.7 (-1.1) Earnings per\" \/>\n<meta property=\"og:url\" content=\"https:\/\/dextechmedical.com\/?p=2256\" \/>\n<meta property=\"og:site_name\" content=\"DexTech\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-25T11:00:28+00:00\" \/>\n<meta name=\"author\" content=\"G\u00f6sta Lundgren\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"G\u00f6sta Lundgren\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/dextechmedical.com\/?p=2256\",\"url\":\"https:\/\/dextechmedical.com\/?p=2256\",\"name\":\"Half-year report July 1 - December 31, 2025 | DexTech\",\"isPartOf\":{\"@id\":\"https:\/\/dextechmedical.com\/#website\"},\"datePublished\":\"2026-02-25T11:00:28+00:00\",\"author\":{\"@id\":\"https:\/\/dextechmedical.com\/#\/schema\/person\/7d6388cae097fcab5953ef5d1733040c\"},\"description\":\"Summary of the second quarter (2025-10-01 \u2013 2025-12-31) Net sales amounted to MSEK 0 (0.0) Operating profit\/loss amounted to MSEK -1.7 (-1.1) Earnings per\",\"breadcrumb\":{\"@id\":\"https:\/\/dextechmedical.com\/?p=2256#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/dextechmedical.com\/?p=2256\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/dextechmedical.com\/?p=2256#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/dextechmedical.com\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Half-year report July 1 &#8211; December 31, 2025\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/dextechmedical.com\/#website\",\"url\":\"https:\/\/dextechmedical.com\/\",\"name\":\"DexTech\",\"description\":\"Ett svenskt forskningsf\u00f6retag specialiserat p\u00e5 urologisk onkologi fr\u00e4mst prostatacancer\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/dextechmedical.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/dextechmedical.com\/#\/schema\/person\/7d6388cae097fcab5953ef5d1733040c\",\"name\":\"G\u00f6sta Lundgren\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/dextechmedical.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/5e00bd305cedebf5b9069290209926ac27dd0b062e7cdfd04870526f70b02470?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/5e00bd305cedebf5b9069290209926ac27dd0b062e7cdfd04870526f70b02470?s=96&d=mm&r=g\",\"caption\":\"G\u00f6sta Lundgren\"},\"sameAs\":[\"https:\/\/dextechmedical.com\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Half-year report July 1 - December 31, 2025 | DexTech","description":"Summary of the second quarter (2025-10-01 \u2013 2025-12-31) Net sales amounted to MSEK 0 (0.0) Operating profit\/loss amounted to MSEK -1.7 (-1.1) Earnings per","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/dextechmedical.com\/?p=2256","og_locale":"en_US","og_type":"article","og_title":"Half-year report July 1 - December 31, 2025 | DexTech","og_description":"Summary of the second quarter (2025-10-01 \u2013 2025-12-31) Net sales amounted to MSEK 0 (0.0) Operating profit\/loss amounted to MSEK -1.7 (-1.1) Earnings per","og_url":"https:\/\/dextechmedical.com\/?p=2256","og_site_name":"DexTech","article_published_time":"2026-02-25T11:00:28+00:00","author":"G\u00f6sta Lundgren","twitter_misc":{"Written by":"G\u00f6sta Lundgren","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/dextechmedical.com\/?p=2256","url":"https:\/\/dextechmedical.com\/?p=2256","name":"Half-year report July 1 - December 31, 2025 | DexTech","isPartOf":{"@id":"https:\/\/dextechmedical.com\/#website"},"datePublished":"2026-02-25T11:00:28+00:00","author":{"@id":"https:\/\/dextechmedical.com\/#\/schema\/person\/7d6388cae097fcab5953ef5d1733040c"},"description":"Summary of the second quarter (2025-10-01 \u2013 2025-12-31) Net sales amounted to MSEK 0 (0.0) Operating profit\/loss amounted to MSEK -1.7 (-1.1) Earnings per","breadcrumb":{"@id":"https:\/\/dextechmedical.com\/?p=2256#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/dextechmedical.com\/?p=2256"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/dextechmedical.com\/?p=2256#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/dextechmedical.com\/en\/"},{"@type":"ListItem","position":2,"name":"Half-year report July 1 &#8211; December 31, 2025"}]},{"@type":"WebSite","@id":"https:\/\/dextechmedical.com\/#website","url":"https:\/\/dextechmedical.com\/","name":"DexTech","description":"Ett svenskt forskningsf\u00f6retag specialiserat p\u00e5 urologisk onkologi fr\u00e4mst prostatacancer","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/dextechmedical.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/dextechmedical.com\/#\/schema\/person\/7d6388cae097fcab5953ef5d1733040c","name":"G\u00f6sta Lundgren","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/dextechmedical.com\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/5e00bd305cedebf5b9069290209926ac27dd0b062e7cdfd04870526f70b02470?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/5e00bd305cedebf5b9069290209926ac27dd0b062e7cdfd04870526f70b02470?s=96&d=mm&r=g","caption":"G\u00f6sta Lundgren"},"sameAs":["https:\/\/dextechmedical.com"]}]}},"_links":{"self":[{"href":"https:\/\/dextechmedical.com\/en\/wp-json\/wp\/v2\/posts\/2260","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dextechmedical.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dextechmedical.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dextechmedical.com\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/dextechmedical.com\/en\/wp-json\/wp\/v2\/comments?post=2260"}],"version-history":[{"count":1,"href":"https:\/\/dextechmedical.com\/en\/wp-json\/wp\/v2\/posts\/2260\/revisions"}],"predecessor-version":[{"id":2263,"href":"https:\/\/dextechmedical.com\/en\/wp-json\/wp\/v2\/posts\/2260\/revisions\/2263"}],"wp:attachment":[{"href":"https:\/\/dextechmedical.com\/en\/wp-json\/wp\/v2\/media?parent=2260"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dextechmedical.com\/en\/wp-json\/wp\/v2\/categories?post=2260"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dextechmedical.com\/en\/wp-json\/wp\/v2\/tags?post=2260"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}